Area M = cheeks, forehead, scalp, and neck.
Area L = trunk and extremities. 
BCC-A Return to Basal Cell and Squamous Cell Skin Cancers

PRINCIPLES OF TREATMENT FOR BASAL CELL SKIN CANCER
The goal of primary treatment of basal cell skin cancer is the cure of the tumor and the maximal preservation of function and cosmesis. All treatment decisions should be customized to account for the particular factors present in the individual case and for patient's preference. Customary age and size parameters may have to be modified.
Surgical approaches often offer the most effective and efficient means for accomplishing cure, but considerations of function, cosmesis, and patient preference may lead to choosing radiation therapy as primary treatment in order to achieve optimal overall results.
In certain patients at high risk for multiple primary tumors, increased surveillance and consideration of prophylactic measures may be indicated.
In patients with low-risk superficial basal cell skin cancer, where surgery or radiation may be contraindicated, local therapy (5-fluorouracil, imiquimod, and photodynamic therapy) may be considered even though the cure rate may be lower.
BCC-B
Return to Basal Cell and Squamous Cell Skin Cancers Add 10%-15% to total and daily doses if using electron beam and add bolus for low-energy electrons.
Maximize fractions to maximize cosmesis.
Radiation therapy is contraindicated in genetic conditions predisposing to skin cancer (eg, nevoid basal cell carcinoma, xeroderma pigmentosum) and connective tissue diseases (eg, lupus, scleroderma). 
BCC-C Return to Basal Cell and Squamous Cell Skin Cancers
SCC-5
Return to Basal Cell and Squamous Cell Skin Cancers Area M = cheeks, forehead, scalp, and neck.
Area L = trunk and extremities. Tumor more than 2 cm but not more than 5 cm in greatest dimension
Tumor more than 5 cm in greatest dimension
Tumor invades deep extradermal structures (i.e., cartilage, skeletal muscle, or bone)
: In the case of multiple simultaneous tumors, the tumor with the highest T category will be classified and the number of separate tumors will be indicated in parentheses, e.g., T2 (5).
Regional lymph nodes cannot be assessed : There is uniform NCCN consensus, based on high-level evidence, that the recommendation is appropriate.
: There is uniform NCCN consensus, based on lowerlevel evidence including clinical experience, that the recommendation is appropriate.
: There is nonuniform NCCN consensus (but no major disagreement), based on lower-level evidence including clinical experience, that the recommendation is appropriate.
: There is major NCCN disagreement that the recommendation is appropriate.
Basal cell and squamous cell skin cancers are the most common human cancers; collectively they are termed non-melanoma skin cancers. In 2005, they are estimated to have an incidence of more than one million cases in the United States; the incidence is rising rapidly. Basal cell carcinomas are about four to five times more common than squamous cell carcinomas. Although rarely metastatic, basal cell and squamous cell cancers can produce substantial local destruction along with disfigurement and may involve extensive areas of soft tissue, cartilage, and bone. The estimated annual cost of treating these two diseases in the United States exceeds $500 million. However, non-melanoma skin cancers generally have a good prognosis.
The most significant environmental carcinogen for non-melanoma skin cancers is sunlight. Thus, individuals in Hawaii are at much greater risk than those in the northern parts of the United States. Fair-skinned individuals who have received too much sun exposure are at the greatest risk for these cancers. Most of these tumors develop on sun-exposed skin sites. The most common sites are on the head and neck area.
The genetics of both basal cell and squamous cell cancers are still being determined. Mutations in the tumor-suppressor PTCH (patched) gene system found on chromosome 9q are present in most of the basal cell cancers. Mutations in the tumor suppressor gene appear to be an early common event in cutaneous squamous cell cancer development. Mutations in several oncogenes (eg, and ) have also been identified. However, in non-melanoma skin cancer development, the role any specific oncogene plays is unclear.
Finally, certain genetic syndromes greatly predispose affected individuals to non-melanoma skin cancer formation, such as albinism (in which skin pigment is absent) xeroderma pigmentosum (in which defects exist in ultraviolet light-induced unscheduled DNA repair), and nevoid basal cell carcinoma syndrome; certain settings of immunosuppression (most notably, organ transplantation) also predispose affected individuals.
In developing the practice guidelines for the treatment of nonmelanoma skin cancer, the NCCN Panel decided to limit the initial algorithms to basal cell and squamous cell cancers, which account for most of the non-melanoma skin cancers. The panel decided to expand the American Joint Committee on Cancer (AJCC) staging system (see ), because more than 95% of basal cell and squamous cell cancers only involve local disease. Thus, the panel decided to develop a more comprehensive stratification system. This stratification system would reflect clinically relevant "levels" or "tiers of difficulty" involved in treating primary tumors.
The NCCN panel examined risk factors for basal cell and squamous cell cancers associated with inadequate treatment of primary tumors (ie, risk factors associated with recurrence and metastasis). For each parameter, the group agreed on specific criteria indicative of when a given tumor is at "high" risk for recurrence or metastasis. If a tumor has any one parameter indicating high-risk behavior, then that tumor enters the high-risk category. In this way, the panel produced specific risk factors for recurrence for basal cell cancer (see ) and for squamous cell cancer (see ).
Several clinical risk factors apply to both basal cell and squamous cell cancers (see and respectively). These risk factors include tumor location and size, the status of tumor borders, whether the tumor is primary or recurrent, certain settings of immunosuppression, and tumors developing in previously irradiated sites.
The NCCN panel elected to group together two separate risk factors: location and size. The science of dividing these factors into low-risk and high-risk categories is somewhat arbitrary because, to a certain extent, both factors, especially size, involve a continuous spectrum of risk.
Location has been known to be a risk factor for non-melanoma skin cancer recurrence and metastasis for many years.
Stated in general terms, both basal cell and squamous cell cancers that develop in the head and neck area are more likely to recur than are those carcinomas developing on the trunk and extremities. Squamous cell carcinomas that develop on the genitalia, mucosal surfaces, and ear are also at greater risk of metastasizing. The concept of a so-called high-risk "mask area of the face" dates back at least to 1983 (see ). Size also has been shown to be a risk factor for non-melanoma skin cancer recurrence. Various different divisions have been used; probably the most common has been "greater than (or less than) 2 cm in diameter."
The NCCN Panel ultimately elected to base the location and size criteria, for the most part, on a 27-year retrospective review of the experience of the Skin Cancer Unit of the New York University (NYU) School of Medicine. This review, published in 1991, evaluated a database containing information on 5755 basal cell cancers. Of the 5755 basal cell cancers evaluated, 2314 primary tumors were treated by curettage and electrodesiccation. Based on modified lifetable 5-year recurrence rates generated in this study, anatomic sites were divided into high-risk, middle-risk, and low-risk sites for recurrence. The high-risk sites correspond roughly to the mask areas of the face (see ). The middle-risk and low-risk sites correspond roughly to the middle-risk and low-risk divisions listed in the algorithms (see and ). In addition, recurrences in the NYU study were significantly more common when tumors in high-risk locations were 6 mm or more in diameter and when tumors in middlerisk locations were 10 mm or more in diameter.
These criteria based on size and location are also more or less in agreement with similar work performed at the national level for the Health Care Financing Administration (HCFA). The HCFA work defined what constitutes high-risk tumors appropriate for Mohs micrographic surgery. 
Additional Clinical Risk Factors for Squamous Cell Carcinoma
The risk factors of well-defined versus ill-defined clinical tumor borders and primary versus recurrent disease have been extensively documented in the biomedical literature.
Settings of immunosuppression, such as organ transplantation as
well as long-term use of psoralen and ultraviolet A light (PUVA), significantly increase the incidence of squamous cell cancer development. Basal cell carcinoma incidence also increases slightly in these settings.
Although several small anecdotal reports describe aggressive tumor behavior in patients with underlying malignancies or individuals taking immunosuppressive medications for non-oncologic diseases, the best data are from the organ transplant literature. The incidence of metastatic squamous cell cancer is significantly greater in this population than in individuals who have not received a transplant. Uncertainty remains whether this is simply because of a greater number of tumors per patient or actually reflects more aggressive tumor behavior at the biological level. Because, collectively, organ transplant recipients have worse outcomes, these patients (see ) and their neoplasms are designated as high risk.
Actually, very little published data suggest basal cell cancers are more likely to recur or metastasize when they develop in immunosuppressed individuals. The only evidence supporting this view includes a few anecdotal clinical reports and several studies documenting laboratory evidence of immunosuppression in these patients. Nevertheless, because of this evidence and the NCCN Panel members' own anecdotal experiences, the panel decided to classify both basal cell and squamous cell cancers that develop in settings of immunosuppression as potentially high-risk tumors.
"Tumors developing in sites of prior radiotherapy" refer to primary non-melanoma skin cancers arising in areas within radiation fields given previously for benign conditions. All recurrent tumors, irrespective of prior therapy, have already been defined as high risk. Again, only a few articles in the biomedical literature support prior radiotherapy for benign conditions as a risk factor for non-melanoma skin cancer recurrence or metastasis.
However, the NCCN panel consensus was this is a valid risk factor.
The NCCN panel identified a few additional clinical parameters that increase the risk of squamous cell cancer only (see ) as follows:
A substantial body of biomedical literature has documented increased rates of metastasis for cutaneous squamous cell cancers arising in the setting of chronic scarring.
In tumors with perineural involvement, clinical symptoms suggesting possible involvement of sensory or motor nerves may occur in up to 40% of cases. Symptoms may include pain, burning, stinging, anesthesia, paresthesia, facial paralysis, diplopia, and blurred vision. Any suggestion of neurologic involvement in the region of a squamous cell cancer should place that tumor in a high-risk category.
Only one article in the biomedical literature documents rapid growth of a cutaneous squamous cell 15 The features of 54 basal cell cancers in young patients referred for Mohs surgery were compared with similar tumors in 1050 older patients. Tumor location, histology, and clinical morphology did not differ appreciably between the two groups. In fact, initial lesion and final defect sizes were statistically smaller in the younger patient group. In a study from the United Kingdom, 39 young basal cell cancer patients were followed for a minimum of 5 years; four tumors were incompletely excised; two recurred and one metastasized. Another study observed a higher number of recurrent tumors in younger women referred for Mohs surgery than in other demographic groups. Finally, two more recent studies found no difference in either recurrence rates or presence of aggressive histologic subtypes in younger versus older patients with basal cell skin cancer.
The NCCN Panel decided, taken together, these studies do not support the suggestion that young age, in and of itself, is a high-risk factor for non-melanoma skin cancer behavior. Any tumor showing an aggressive histologic growth pattern, regardless of the patient's age, becomes a high-risk tumor based on that histology.
Histologic subtyping of basal cell cancer as a predictor of risk of recurrence is a well-established concept. The subtypes encompassed by the term "aggressive growth pattern"-including the micronodular, infiltrative, sclerosing, and morpheaform (or desmoplastic) patterns-are more likely to recur than the nodular and superficial basal cell cancers.
The NCCN Panel elected to include the entity "basosquamous carcinoma" (also sometimes called "metatypical basal cell cancer") under the category of squamous cell cancer rather than basal cell cancer. Some basosquamous tumors probably represent collision tumors in which a basal cell cancer and a squamous cell cancer developed in close proximity to one another. Others possibly represent biopsied regions of a true basal cell cancer that are inflamed and have undergone squamous metaplasia. Nevertheless, several studies suggest basosquamous carcinoma has a metastatic capacity more like squamous cell cancer than basal cell cancer.
For this reason, the panel felt these tumors are best conceptualized as squamous cell cancers until other, more instructive, data become available.
Perineural involvement poses a greatly increased risk of recurrence, whether the tumor is a basal cell or squamous cell cancer, and an increased risk of metastasis for Guidelines Index Basal Cell and Squamous Cell TOC Staging, MS, References squamous cell cancer, Although perineural involvement is uncommon in any non-melanoma skin cancer, it develops much more frequently in squamous cell than in basal cell cancer.
In their extensive meta-analysis of risk factors for local recurrence and metastasis of squamous cell cancer, Rowe and colleagues found that patients with welldifferentiated tumors fared significantly better than those patients with poorly differentiated lesions. Although Broders originally divided squamous cell cancers histologically into four groups or grades, the modern trend has been to reduce the divisions to two groups: (1) well-differentiated, and (2) moderately differentiated, poorly differentiated, or undifferentiated. The NCCN Panel has adopted this modern approach in these guidelines.
The panel members discussed whether any other histologic parameters should be included as risk factors for squamous cell cancer (see ) beside the degree of differentiation and perineural involvement.
After some discussion, the NCCN Panel elected to maintain the histologic subtypes of adenoid (or acantholytic) and adenosquamous (or mucin-producing) squamous cell cancer as markers for an increased risk of recurrence or metastasis. Again, few studies document the prognostic significance of these subtypes.
Even so, because these tumors probably would not be included in the high-risk category on the basis of their degree of differentiation, the panel decided to list them as separate risk factors.
One histologic feature reported in the biomedical literature is the presence of desmoplasia. In a study from Germany, desmoplastic cutaneous squamous cell cancer was shown to pose a greatly increased risk of both recurrence and metastasis. After some discussion, the panel elected to include this histologic subtype as a risk factor for aggressive squamous cell cancer behavior.
Finally, a small, somewhat older, body of biomedical literature found an association between invasion of squamous cell cancer into the deep reticular dermis or subcutaneous fat (corresponding to a Clark level IV or V melanoma) and aggressive behavior. Several more studies have suggested squamous cell tumor depth, as measured in millimeters (similar to Breslow's original work with melanoma), may also have prognostic value. Although there was some discussion, a meta-analysis of squamous cell cancer risk factors for recurrence and metastasis found both types of depth measurements have prognostic value. Therefore, the panel decided to include these two risk factors and used the division points determined by Rowe and colleagues in the algorithm (see ).
One final note should be made regarding squamous cell cancer histology. The panel elected to include full-thickness atypia, or "squamous cell cancer in situ," in the algorithm. Although the risk of metastasis from in situ disease is negligible, the risk of recurrence---as with the superficial form of basal cell cancer---depends on the presence or absence of any of the risk factors listed in the algorithm (see ).
The presence or absence of an infiltrative component at the advancing border of a squamous cell tumor was one parameter the NCCN Panel discussed. Some authors have advocated this parameter as a risk factor. However, the pathologists on the panel believe this feature usually correlates well with the degree of differentiation, and it is a descriptive term Guidelines Index Basal Cell and Squamous Cell TOC Staging, MS, References not routinely applied to squamous cell cancer. Consequently, this parameter was excluded.
Similarly, the histologic subtype termed "spindle cell squamous cell cancer" has been associated with perineural invasion which, in and of itself, is a risk factor for aggressive squamous cell cancer behavior. However, the panel decided this indirect association did not warrant the listing of spindle cell squamous cell cancer as a separate risk factor.
The NCCN Panel developed recommendations for the identification and management of patients at high risk for squamous cell skin cancer (see ). Two members of the International Transplantation Skin Cancer Collective assisted the NCCN Panel in this process and provided expert input. Certain populations of individuals, chiefly those with the nevoid basal cell carcinoma syndrome, are at risk for the development of multiple basal cell cancers; however, the panel felt that the existing basal cell cancer algorithm provides reasonably adequate guidance for care of these patients.
On clinical presentation of the patient with a suspicious lesion, workup of both basal cell and squamous cell cancers begins with a history and physical examination. For basal cell cancer, the emphasis is on a complete skin examination. For squamous cell cancer, the emphasis is on a complete skin and regional lymph node examination. A full skin examination is recommended, because individuals with a skin cancer often have additional, concurrent precancers or cancers located at other, usually sun-exposed, skin sites. These individuals are also at increased risk of developing cutaneous melanoma.
A skin biopsy is then performed on any suspicious lesion. The biopsy should include reticular dermis if the lesion is suspected to be more than a superficial process. This procedure is preferred, because an infiltrative histology may sometimes be present only at the deeper, advancing margins of a tumor, and superficial biopsies will frequently miss this component. Skin lesions in high-risk populations (see ) may be difficult to assess clinically; therefore, a low threshold for performing skin biopsies in these patients is necessary. In patients with squamous cell cancer, the presence of a palpable regional lymph node should prompt a fine-needle aspiration (FNA) for diagnosis. If the aspiration is positive, imaging should be done as clinically indicated. If the aspiration is negative, an open biopsy should be performed. Uncommonly, skin cancers may present with the appearance of deep extension, for example, into bone or the orbit. In such cases, preoperative imaging studies may be useful to help assess the extent of soft tissue or bony involvement.
The algorithms list all of the therapies currently used to treat localized non-melanoma skin cancer, including surgical techniques (ie, curettage and electrodesiccation, excision with postoperative margin assessment [POMA], Mohs surgery or excision with "complete circumferential peripheral and deep-margin assessment" [CCPDMA] ) and radiation therapy (RT). For basal cell carcinoma, surgery and radiotherapy appear to be the most effective treatments; in an evidence-based review of the literature, the best results were obtained with surgery. In patients with low-risk squamous cell The curettage and electrodesiccation technique is deemed effective for low-risk tumors with two caveats. The first caveat states that this technique should not be used to treat hair-bearing sites because of the risk that a tumor, which extends down follicular structures, might not be adequately removed.
The second caveat states that if the subcutaneous layer is reached during the course of surgery, then surgical excision must be performed instead of curettage and electrodesiccation. This change in therapy is necessary, because the effectiveness of the curettage and electrodesiccation technique rests on the ability of the clinician to distinguish between firm, normal dermis and soft tumor tissue when using a sharp curette. Because subcutaneous fat is even softer than tumor tissue, the ability of the curette to distinguish and, therefore, to selectively and completely remove tumor cells, disappears.
Another therapeutic option for both basal cell and squamous cell cancers is POMA, consisting of standard surgical excision followed by postoperative pathologic assessment of margins. If lesions can be excised with the recommended margins, then sideto-side closure, skin grafting, or secondary intention healing (ie, all closures do not rotate tissue around and alter where residual "seeds" of tumor might be sitting) are all appropriate reconstructive approaches. However, if tissue rearrangement or skin graft placement is necessary to close the defect, the group believes intraoperative surgical margin assessment is necessary.
Either Mohs surgery or excision with CCPDMA using intraoperative frozen section (IOFS) assessment is the recommended therapeutic approach for all high-risk tumors. It should be noted that IOFS is not acceptable as an alternative to Mohs surgery unless it includes a complete assessment of all deep and peripheral margins. The descriptive term CCPDMA underscores the panel's belief that intraoperative assessment of all tissue margins is the key to complete tumor removal. Mohs surgery is preferred because of its documented efficacy.
If Mohs surgery is unavailable, complete tissue margin assessment must still be performed in another fashion. Consequently, the emphasis is placed on CCPDMA. For certain highrisk squamous cell lesions, sentinal lymph node mapping may be considered, although the benefit of this technique has yet to be proven.
Curettage and Electrodesiccation
Excision
The role of RT was probably the single largest source of disagreement among the NCCN Panel of experts. The panel was initially divided into two groups on this issue: (1) the radiation oncologists wanted to use this therapy for almost all tumors, whereas (2) the surgeons did not want to use RT.
A large biomedical literature review was performed and circulated among the participants, followed by a panel discussion of the evidence. A reasonable consensus was achieved after the surgeons realized that , RT can result in very good cure rates and excellent cosmesis. The radiation oncologists agreed in order to achieve those cure rates and cosmesis, RT . In other words, the details of RT are important and need to be included in the algorithms.
The panel consensus is that adequate training in the techniques of Mohs micrographic surgery and RT are essential to achieve high cure rates when treating non-melanoma skin cancers. If either of these approaches is inappropriately or inadequately applied and performed, less than optimal cure rates will result.
The size and location criteria for RT were expanded to include tumors in high-risk locations up to 15 mm in diameter and tumors in middle-risk locations up to 20 mm in diameter. The low-risk regions of the trunk and extremities are not usually treated with RT; the genitalia, hands, and feet are also excluded. Verrucous carcinoma is excluded, because several reports in the biomedical literature document an increased metastatic risk after RT in patients with this generally low-grade malignancy. RT is also contraindicated in genetic conditions predisposing to skin cancer (eg, xeroderma pigmentosum) and connective tissue diseases (eg, lupus, scleroderma).
To assist users of the guidelines, the panel arrived at several principles of primary treatment for both basal cell and squamous cell cancer (see and ). These principles were developed to suggest the importance of customizing any and all therapeutic approaches to the particular factors and to the individual needs of each patient. Specifics about the application of RT, including caveats regarding different types of therapeutic radiation and total doses and fractionation ranges, are shown in the algorithms (see and ).
Finally, all of the panel members agreed RT is generally most appropriate in older individuals because of a tendency for cosmesis to wane and a risk of additional non-melanoma skin cancer to develop within a radiation field, typically after 10 to 20 years. However, the definition of "older" varied somewhat. Everyone agreed 55 years of age was an acceptable middle ground in terms of a cut off for the use of radiotherapy in most instances. Again, the principles of primary treatment of basal cell and squamous cell cancers (see and ) were developed to address this issue. If tissue margins are positive after Mohs surgery or a CCPDMA equivalent of a skin cancer, the case should be presented to a multidisciplinary tumor board and clinical trials should be considered (see and ).
Patients with positive findings on either FNA or open biopsy of a lymph node should receive regional lymph node dissection. A palpable intraparotid mass, in the presence of a facial tumor, should be treated with superficial parotidectomy. In both settings, adjuvant radiotherapy should be considered if more than one lymph node greater than 3 cm in diameter is present, or if there is any evidence of extracapsular spread. Specifics about the application of RT (including caveats regarding different types of therapeutic radiation, total doses, and fractionation ranges) are shown in the algorithms (see and ).
Suggestions for the care of patients at high risk for squamous cell cancer are listed in the algorithm (see ).
Two well-established points about patients with non-melanoma skin cancer underlie the follow-up schedules. One point is that 30% to 50% of these patients will develop another non-melanoma skin cancer during a 5-year follow-up period. They are also at increased risk of developing cutaneous melanoma. Therefore, continued long-term surveillance of these patients is essential, as is patient education about the values of sun protective behavior and regular self examination of the skin (see and ). A second point is that 70% to 80% of all cutaneous squamous cell cancer recurrences develop within 2 years of the initial therapy. Therefore, close follow-up of these patients during this time period is critical.
Finally, for the management of local tumor recurrence or regional metastasis of squamous cell cancer, the algorithm directs clinicians to follow the appropriate pathways for primary treatment. The case should be presented to a multidisciplinary tumor board and clinical trials should be considered if the following develops: (1) any form of basal cell metastasis, or (2) a regional recurrence of squamous cell cancer or the development of distant disease. 83 
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